杨子峰教授，博士，国务院特殊津贴专家，现任广州呼吸健康研究院副院长 呼吸疾病全国重点实验室副主任。
在紧扣临床需求的呼吸系统传染病、重大呼吸慢病的动物模型构建及重大呼吸系统传染病及慢病的创新药物研发领域有丰富的研究经验及成果。主持多项国家自然科学基金和国家重点研发计划，已在Science、New England、Nature子刊等国际高水平期刊发表100多篇文章，影响因子逾1000，单篇最高被引802次，H指数30。申请国家、国际发明专利近30余项，授权20余项。荣获国家科技进步创新团队奖、广东省科技进步特等及一等奖、广东省丁颖科技奖、教育部科技进步二等奖等多项科技奖励。
【研究方向】
中西医结合防治呼吸道病毒感染
【科研项目】
1.国家自然科学基金专项项目，临床价值导向的新冠病毒3CLpro单药口服抑制剂的长效机制研究及研发，2024-1-1至2026-12-31，200万，在研，主持
2.国家自然科学基金国际(地区)合作与交流项目，基于自适应Fourier分解模型的人季节性流感病毒血 凝素蛋白抗原进化精准预测研究，2024-1-1至2026-12-31，160万，在研，主持
3.国家重点研发计划，冬奥会相关人群新冠疫情传播风险链分析技术，2021.4-1至2022-6-30，82万，已结题，主持
4.国家自然科学基金面上项目，基于中药单体连翘苷抗新冠活性发现靶向病毒生命周期蛋白及其免疫炎症调控机制研究，2022.1-1至2025-12-31，56万，在研，主持
5.国家自然科学基金面上项目，板蓝根源甾类化合物靶向调控流感诱导的固有免疫过度炎症的机制研究，2019.01--1至2022-12-31,57万，已结题，主持
6.国家重点研发计划，病毒和细菌混合感染对慢阻肺相关炎症反应影响研究，2017.7-1至2020-12-31,189万，已结题，主持
7.国家自然科学基金国际(地区)合作与交流项目，基于糖组学技术的受体糖基化在流感病毒跨物种传播中的作用及中药抗病毒有效成分的研究，2017.1-1至2019-12-31，104.15万，已结题，主持
8.国家自然科学基金面上项目，树鼩H9N2禽流感模型的建立及其免疫致病机制的研究，2015.01-1至2018-12-31,150万，已结题，主持
【代表性论文及著作】
(1) Yang ZF#,Mok CKP# ,Peiris JSM, Zhong NS*.Human Infection with a Novel Avian Influenza A(H5N6) Virus , N Engl J Med , 2015, 373(5): 487~489
(2) Yang ZF#,Leung ELH#,Liu L,Jiang ZH,Zhong NS*.Developing influenza treatments using traditional Chinese medicine , Science, 2015, 347(6219 Suppl): S35~S37
(3) Zifeng Yang#, Zhengtu Li#, Yangqing Zhan#, Zhengshi Lin#, Zhonghao Fang#, Xiaowei Xu#, Lin Lin#, Haijun Li#, Zejun Lin, Changyuan Kang, Jingyi Liang, Shiwei Liang, Yongming Li, Shaoqiang Li, Xinyun Yang, Feng Ye, Nanshan Zhong*.Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection: a multi-center, double-blind, randomized, placebo-controlled phase 2 trial,lancet infectious diseases,2024,24(5):535-545
(4) Xiaoxin Chen #, Xiaodong Huang #, Qinhai Ma #, Petr Kuzmič #, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jinsong Liu, Tianyu Zhang, James Spencer, Zhenzhen Zhu, Wenbin Deng, Xinwen Chen, Shu-Hui Chen, Nanshan Zhong*, Xiaoli Xiong*, Zifeng Yang*.Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 with improved pharmacokinetics compared to nirmatrelvir.nature microbiology,2024,9(4):1075-1088
(5) Wenda Guan#, Rong Qu#, Lihan Shen#, Kailin Mai#, Weiqi Pan#, Zhengshi Lin#, Liping Chen, Ji Dong , Jiawei Zhang , Pei Feng , Yunceng Weng , Minfei Yu, Peikun Guan, Jinchao Zhou, Chuanmeizi Tu, Xiao Wu, Yang Wang, Chunguang Yang , Yun Ling , Sheng Le , Yangqing Zhan, Yimin Li , Xiaoqing Liu, Heyan Zou, Ziqi Huang , Hongxia Zhou, Qiubao Wu, Wenjie Zhang, Jiayang He, Teng Xu, Nanshan Zhong*, Zifeng Yang*.Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus.MED,2024,S2666-6340(23)00361-6.
(6)Lei Luo#,Zifeng Yang#,Jingyi Liang#,Yu Ma#,Hui Wang#,Chitin Hon#, Mei Jiang#,Zhengshi Lin,Wenda Guan,Zhitong Mai,Yongming Li,Kailin Mai, Zhiqi Zeng,Chuanmeizi Tu,Jian Song,Bin Liu, Yong Liu,Jianfeng He, Huiyuan Li,Bosheng Li,Hang Dong,Yutian Miao,Shujun Fan,Lirui Fan, Xingyi Liang,Ke Li,Chun Chen,Huihong Deng*,Zhicong Yang*,Nanshan Zhong*.Crucial control measures to contain China's first Delta variant outbreak. Natl Sci Rev.2022, 9(4):nwac004
(7)Jingyi Liang#, Ruibin Liu#, Wei He#, Zhiqi Zeng, Yangqianxi Wang, Boyuan Wang, Lixi Liang, Tong Zhang, C L Philip Chen, ChiWai Chang, Chitin Hon*, Eric H Y Lau*, Zifeng Yang*, KaLok Tong*.Infection rates of 70% of the population observed within 3 weeks after release of COVID-19 restrictions in Macao, China.J Infect2023,86(4):402-404
(8)Jingyi Liang#, Zhufeng Wang#, Yong Liu#, Linxiu Zeng, Zhengtu Li, Jiamin Liang, Hanwen Liang , Mei Jiang*, Zifeng Yang*. Epidemiology and co-infection patterns in patients with respiratory tract infections in southern China between 2018 and 2020, J Infect,2021, 83(3):e6-e8
(9)Mok, CKP#,Guan WD#,Liu XQ#,Lamers MM#,Li XB,Wang M,Zhang TJS;Zhang QL,Li ZT,Huang JC,Lin JY,Zhang YH,Zhao P,Lee, HHY,Chen L,Li YM,Peiris JSM,Chen RC,Zhong NS,Yang ZF*.Genetic Characterization of Highly Pathogenic Avian Influenza A(H5N6) Virus, Guangdong, China ,Emerg Infect Dis,2015, 21(12): 2268~2271
(10) Chen Hua#, Qinhai Ma#, Yun Zhu#, Shuai Xia, Zezhong Liu, Lin Li, Lu Lu,Nanshan Zhong,Shuwen Liu*,Zifeng Yang*,Shibo Jiang*.Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation, Signal Transduct Target Ther.2021; 6(1):318.
(11)Li RF#,Yuan B#,Xia XS# ,Zhang S,Du QL,Yang CG,Li N,Zhao J,Zhang YH, Zhang RP,Feng Y,Jiao JL,Peiris M,Zhong NS,Mok CKP*; Yang ZF*.Tree shrew as a new animal model to study the pathogenesis of avian influenza (H9N2) virus infection, Emerg Microbes Infect, 2018, 7(1): 166~170
(12) Bei Wang , Hai-Jun Li , Mi-Mi Cai , Zhao-Xin Lin, Xia-Fei Ou, Shu-Hua Wu, Rui-Huan Cai, Ying-Na Wei, Fei Yang, Ya-Min Zhu, Zi-Feng Yang* , Nan-Shan Zhong* , Ling Lin*.Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2,single centre, randomised, double-blind, placebo-controlled Trial. EClinicalMedicine,2023,63:102189
(13)Yangqing Zhan#, Zhengshi Lin#, Jingyi Liang#, Ruilin Sun#, Yueping Li#, Bingliang Lin#, Fangqi Ge#, Ling Lin#, Hongzhou Lu#, Liang Su, Tianxin Xiang, Hongqiu Pan, Chaolin Huang , Ying Deng , Furong Wang , Ruhong Xu, Dexiong Chen, Ping Zhang, Jianlin Tong, Xifu Wang, Qingwei Meng, Zhigang Zheng, Shuqiang Ou, Xiaoyun Guo, Herui Yao, Tao Yu , Weiyang Li, Yu Zhang, Mei Jiang, Zhonghao Fang, Yudi Song , Ruifeng Chen, Jincan Luo, Changyuan Kang, Shiwei Liang, Haijun Li; other Collaborative Institutes; Jingping Zheng*, Nanshan Zhong*, Zifeng Yang*.Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.EClinicalMedicine,2023,67:102359
【所获荣誉和奖励】
科技奖励：
l 国家科技进步奖创新团队奖
l 广东省科技进步一等奖
l 广东省科技进步特等奖
l 全国创新争先奖牌
l 广东省丁颖科技奖
l 教育部科技进步二等奖
l 云南省科技进步奖二等奖
l 中国专利优秀奖
l 中华中医药学会科学技术奖中青年创新人才奖
人才荣誉：
l 国务院政府特殊津贴专家
l 广州市优秀专家
l 广州市医学领军人才
l 广州市医学重点人才
